Tenderwize
Zurück zur Suche

Open-house rebate agreement for Paliperidone depot formulations

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 03, 2027 · 371 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Paliperidon, in 3-Monats-Depot-Darreichungsformen, ATC N05AX13

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

52 / 100

Komplexität

48 / 100

Risikofaktoren

Submitting documents in the wrong DTVP area is explicitly prohibited; the notice says the contract documents must not b...

To obtain contract start on the next month’s first day, complete and correct documents must be received by the 3rd of t...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Non-exclusive rebate agreement for pharmaceutical products: Paliperidone in 3-month depot dosage forms (ATC N05AX13).
  • Open-house model with identical, non-individually negotiable contract terms for all eligible pharmaceutical companies.
Vollständige Zusammenfassung anzeigen

This is an open-house supply arrangement by AOK Bayern for Paliperidone in 3-month depot formulations (ATC N05AX13). It is not a competitive award procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 01.11.2025 to 31.10.2027, with contract entry possible at any time until 03.09.2027. Submission is electronic via DTVP with a qualified electronic signature or by signed paper originals in duplicate; German language is required, and non-German documents must include a German translation.

Risiken

Submitting documents in the wrong DTVP area is explicitly prohibited; the notice says the contract documents must not b...

To obtain contract start on the next month’s first day, complete and correct documents must be received by the 3rd of t...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Paliperidone depot formulations

Supply arrangement for Paliperidone in 3-month depot dosage forms (ATC N05AX13). The lot is an open-house rebate agreement, not a selective tender. Contract terms are pre-set and non-negotiable. Performance is in Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Oct 2025 - Oct 2027

Kategorie

Pharmaceutical products

Frist

Deadline Sep 03, 2027

Vergabedetails

Veröffentlichungsdatum
14 Sep 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
602050-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30